AVILEX PHARMA ApS: Financial statements 2020
CVR: 34896828
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
AVILEX PHARMA ApS (CVR 34896828) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK -3,132,649 and a net result of DKK -3,041,705 compared with DKK -3,726,433 the year before. Equity in the 2020 report amounted to DKK -18,649,293. The company had 2 employees in the financial year.
- Gross Profit
- DKK -3,132,649
- Profit/Loss
- DKK -3,041,705
- Equity
- DKK -18,649,293
- Total Assets
- DKK 9,374,989
- Employees
- 2
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | -3.1 mio. | -3 mio. | -18.6 mio. | 2 |
| 2019 | - | - | -3.7 mio. | -15.6 mio. | 4 |
| 2018 | - | - | -3.9 mio. | -11.9 mio. | 1 |
| 2017 | - | - | -2.4 mio. | -8.1 mio. | 1 |
| 2016 | - | - | -5.5 mio. | -5.7 mio. | 1 |
Official annual report
How creditworthy is AVILEX PHARMA ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
As of December 31, 2020, Beierholm Godkendt Revisionspartnerselskab has been appointed auditor of AVILEX PHARMA ApS.
As of December 31, 2020, Grant Thornton, Godkendt Revisionspartnerselskab has stepped down as auditor of AVILEX PHARMA ApS.
AVILEX PHARMA ApS has published its annual report for 2019. The net result was DKK -3,726,433.
About AVILEX PHARMA ApS
AVILEX PHARMA ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2012. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Kristian Strømgaard. The board consists of Raymond George Hill (chair), Camilla Petrycer Hansen, Jonathan Mark Treherne and Kristian Strømgaard. The company's owners include Novo Holdings A/S, MIKAEL SØNDERGÅRD THOMSEN ApS and KRISTIAN STRØMGAARD HOLDING ApS. The company has 3 employees (2018). In 2025, the company reported a net result of DKK -4,530,000 compared with DKK -4,428,000 the year before. Equity in the 2025 report amounted to DKK -10,797,000.